Anti-CD16 monoclonal antibody - Sanofi Genzyme/MacroGenics

Drug Profile

Anti-CD16 monoclonal antibody - Sanofi Genzyme/MacroGenics

Alternative Names: anti-CD16; CD16 Mab; GMA-161

Latest Information Update: 15 Dec 2016

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Genzyme Corporation; MacroGenics
  • Class Monoclonal antibodies
  • Mechanism of Action IgG receptor antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Discontinued Immune thrombocytopenic purpura; Immunological disorders

Most Recent Events

  • 29 Oct 2003 Preclinical trials in Immunological disorders in USA (unspecified route)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top